In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

Executive Summary

The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.


Related Content

Retinal Disease: Much Progress, Some Pain
Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012
Biotech’s Declaration Of Independence And What Pharma Needs To Do About It
Eylea Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms
A Bad Day for Lucentis
Avastin v. Lucentis: An Early Test Case For Medicare ACOs
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Ironwood Pharmaceuticals: Independent for the Long Haul
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Bayer/Regeneron: Typically Rich, Extra Regional


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts